Nobel Prize in Physiology for HCV pioneers
The Nobel Prize in Physiology or Medicine goes to Harvey J. Alter, Michael Houghton and Charles M. Ric
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1122 entries already.
Entries by Thomas Gabrielczyk
Swiss Sophia Genetics to expand globally
/in News/by Thomas GabrielczykSwiss Sophia Genetics has raised $110m, to expand marketing of its AI-driven cancer and genetic disease decision support platform globally.
EIB and EC launch circular bioeconomy fund
/in News/by Thomas GabrielczykThe European Commission (EC) and the European Investment Bank (EIB) have launched a circular bioeconomy fund with a target size of 250m. ·
Dewpoint Therapeutics raise $77m in Series B financing
/in News/by Thomas GabrielczykA $77 Series B financing allows Dewpoint Therapeutics Inc to select a lead programme from its new drug class of molecular condensates and push proof-of-concept studies.
Kurma Partners close diagnostics fund at 50m
/in News/by Thomas GabrielczykThe only investment fund dedicated to breakthrough diagnostics, Kurma Diagnostics 2, had its first closing at 50m.
Danish Galecto Inc. secures US$64m equity financing
/in News/by Thomas GabrielczykDanish fibrosis and cancer specialist Galecto Inc. has raised US$64m in a Series B round led by Soleus Capital.
MosaMeat NV bags US$55m financing
/in News/by Thomas GabrielczykMaastricht-based cultured meat producer Mosa Meat NV has raised $55m in a Series B financing, bringing its funding to $63.8m.
Pureos Bioventures closes US$170m fund
/in News/by Thomas GabrielczykNewly formed venture capitalist Pureos Bioventures has set up a US$170m fund dedicated to Swiss and European drug developers.
Biotechs request money for COVID therapeutics
/in News/by Thomas GabrielczykGerman biotech companies and their industry association BIO Deutschland have called for appropriate investments into clinical COVID-19 therapies.
Polyneuron Pharmaceuticals AG extends Series A financing
/in News/by Thomas GabrielczykSwiss auto-immunity specialist Polyneuron Pharmaceuticals AG has received CHF14m from HBM Healthcare Investments.